EmpowerPharm Inc., a clinical-stage pharmaceutical company dedicated to research and clinical advancement, disclosed today that the last participant concluded the treatment and active involvement in the Company-sponsored Phase II clinical investigation. EmpowerPharm is the sponsor of EPI-CBD-001 (NCT05600114), a multicenter, randomized, double-blind, parallel-group, placebo-controlled study focused on assessing the effectiveness, safety, and tolerability of cannabidiol in individuals with Social Anxiety Disorder. This pivotal Phase II study involved the enrollment of 239 patients from 19 clinical centers across the United States.
T 416.291.2580 E firstname.lastname@example.org
Copyright © 2024 EmpowerPharm Inc. • All Rights Reserved